Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Telomere length predicts progression and overall survival in chronic lymphocytic leukemia: data from the UK LRF CLL4 trial

Your institute does not have access to this article

Relevant articles

Open Access articles citing this article.

Access options

Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Figure 1


  1. Lin TT, Letsolo BT, Jones RE, Rowson J, Pratt G, Hewamana S et al. Telomere dysfunction and fusion during the progression of chronic lymphocytic leukemia: evidence for a telomere crisis. Blood 2010; 116: 1899–1907.

    CAS  Article  Google Scholar 

  2. Jones CH, Pepper C, Baird DM . Telomere dysfunction and its role in haematological cancer. Br J Haematol 2012; 156: 573–587.

    CAS  Article  Google Scholar 

  3. Rossi D, Lobetti Bodoni C, Genuardi E, Monitillo L, Drandi D, Cerri M et al. Telomere length is an independent predictor of survival, treatment requirement and Richter's syndrome transformation in chronic lymphocytic leukemia. Leukemia 2009; 23: 1062–1072.

    CAS  Article  Google Scholar 

  4. Roos G, Kröber A, Grabowski P, Kienle D, Bühler A, Döhner H et al. Short telomeres are associated with genetic complexity, high-risk genomic aberrations, and short survival in chronic lymphocytic leukemia. Blood 2008; 111: 2246–2252.

    CAS  Article  Google Scholar 

  5. Mansouri L, Grabowski P, Degerman S, Svenson U, Gunnarsson R, Cahill N et al. Short telomere length is associated with NOTCH1/SF3B1/TP53 aberrations and poor outcome in newly diagnosed chronic lymphocytic leukemia patients. Am J Hematol 2013; 88: 647–651.

    CAS  Article  Google Scholar 

  6. Grabowski P, Hultdin M, Karlsson K, Tobin G, Aleskog A, Thunberg U et al. Telomere length as a prognostic parameter in chronic lymphocytic leukemia with special reference to VH gene mutation status. Blood 2005; 105: 4807–4812.

    CAS  Article  Google Scholar 

  7. Sellmann L, de Beer D, Bartels M, Opalka B, Nückel H, Dührsen U et al. Telomeres and prognosis in patients with chronic lymphocytic leukaemia. Int J Hematol 2011; 93: 74–82.

    Article  Google Scholar 

  8. Skowronska A, Parker A, Ahmed G, Oldreive C, Davis Z, Richards S et al. Biallelic ATM inactivation significantly reduces survival in patients treated on UK CLL4 trial. J Clin Oncol 2012; 30: 4524–4532.

    CAS  Article  Google Scholar 

  9. Rose-Zerilli M, Forster J, Parker H, Parker A, Rodriguez A, Chaplin T et al. ATM mutation rather than BIRC3 deletion and/or mutation predicts reduced survival in 11q-deleted chronic lymphocytic leukemia, data from the UK LRF CLL4 trial. Haematologica 2014; 99: 736–742.

    CAS  Article  Google Scholar 

  10. Oscier DG, Rose-Zerilli MJJ, Winkelmann N, Gonzalez de Castro D, Gomez B, Forster J et al. The clinical significance of NOTCH1 and SF3B1 mutations in the UK LRF CLL4 trial. Blood 2013; 120: 4441–4443.

    Google Scholar 

  11. Oscier D, Wade R, Davis Z, Morilla A, Best G, Richards S et al. Prognostic factors identified three risk groups in the LRF CLL4 trial, independent of treatment allocation. Haematologica 2010; 95: 1705–1712.

    CAS  Article  Google Scholar 

  12. Gonzalez D, Martinez P, Wade R, Hockley S, Oscier D, Matutes E et al. Mutational status of the TP53 gene as a predictor of response and survival in patients with chronic lymphocytic leukemia: results from the LRF CLL4 trial. J Clin Oncol 2011; 29: 2223–2229.

    Article  Google Scholar 

  13. Catovsky D, Richards S, Matutes E, Oscier D, Dyer MJ, Bezares RF et al. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. Lancet 2007; 370: 230–239.

    CAS  Article  Google Scholar 

  14. Lin TT, Norris K, Heppel NH, Pratt G, Allan JM, Allsup DJ et al. Telomere dysfunction accurately predicts clinical outcome in chronic lymphocytic leukaemia, even in patients with early stage disease. Br J Haematol 2014; 167: 214–223.

    Article  Google Scholar 

  15. Jebaraj BM, Busch R, Zenz T, Bühler A, Winkler D, Schnaiter A et al. Telomere length and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial. Blood 2013; 122: 671.

    Google Scholar 

Download references

Author information

Authors and Affiliations


Corresponding authors

Correspondence to J C Strefford or D G Oscier.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Additional information

Supplementary Information accompanies this paper on the Leukemia website

Supplementary information

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Strefford, J., Kadalayil, L., Forster, J. et al. Telomere length predicts progression and overall survival in chronic lymphocytic leukemia: data from the UK LRF CLL4 trial. Leukemia 29, 2411–2414 (2015).

Download citation

  • Published:

  • Issue Date:

  • DOI:

Further reading


Quick links